Description
Retatrutide (LY3437943) is an investigational triple-agonist peptide that simultaneously activates the GLP-1, GIP, and glucagon receptors. Developed by Eli Lilly, it is designed to enhance metabolic regulation, reduce appetite, increase energy expenditure, and improve glucose control. Early clinical studies show unprecedented levels of weight reduction, making retatrutide one of the most promising next-generation metabolic therapeutics. It is currently being evaluated for obesity, type 2 diabetes, and metabolic disorders.
Please note: For hygiene reasons, we are unable to offer refunds or exchanges.
Damaged items must be reported to us within 48 hours of delivery to or via WhatsApp. Please do not dispose of the damaged items without prior written confirmation from us as we may require the product to be returned to us for further examination or to undergo an investigation. We cannot accept claims of items being damaged, broken, or missing after this time. By purchasing any of our products, the buyer accepts our return policy.
Your order will be carefully prepared and dispatched within 2 business days. Please allow 3–5 business days for your parcel to arrive. A confirmation email will be sent to you as soon as your order is on its way.







